{
  "ticker": "LLY",
  "timestamp": "2025-12-01T09:26:16.549709",
  "analysis_date": "2024-12-19",
  "historical_mode": true,
  "portfolio_value": 100000.0,
  "verdict": "REJECT",
  "final_position_pct": 0,
  "final_position_dollars": 0.0,
  "confidence": "LOW",
  "reasoning": "Despite the bullish sentiment surrounding Eli Lilly (LLY) due to the FDA's resolution of the GLP-1 drug shortage, the overall recommendation from our research manager is to HOLD with low confidence. The inability to conduct a comprehensive analysis due to a synthesis failure raises significant concerns about the robustness of our investment thesis. Given these uncertainties and the mixed evaluator opinions, it is prudent to pass on this trade to mitigate risk.",
  "key_factors": [
    "FDA decision on GLP-1 drug",
    "Low confidence in analysis",
    "Mixed evaluator opinions"
  ],
  "conditions": [
    "Inability to generate full analysis",
    "Default to HOLD recommendation"
  ],
  "stop_loss_pct": 15,
  "profit_targets": [
    12.5,
    18.8,
    25
  ],
  "guardrail_corrections": [],
  "is_llm_decision": true,
  "risk_controls": {
    "stop_loss": {
      "percentage": 15,
      "dollar_amount": 0.0
    },
    "take_profit": {
      "targets": [
        12.5,
        18.8,
        25
      ],
      "scale_out": [
        0.33,
        0.33,
        0.34
      ]
    },
    "time_limit": {
      "max_holding_period": "90 days",
      "review_frequency": "weekly"
    }
  },
  "risk_consensus": {
    "stances": {
      "aggressive": "STRONG BUY",
      "neutral": "BUY",
      "conservative": "MINIMAL BUY"
    },
    "position_sizes": {
      "aggressive": 15.0,
      "neutral": 12.0,
      "conservative": 2.0
    },
    "agreements": [
      "All evaluators favor buying"
    ],
    "conflicts": [],
    "avg_position_size": 0.09666666666666666,
    "red_flags": [
      {
        "flag": "Analysis failed",
        "severity": "HIGH",
        "source": "System"
      }
    ]
  },
  "position_sizing": {
    "range_min_pct": 0.0,
    "range_max_pct": 0.0,
    "final_pct": 0,
    "final_dollars": 0.0
  },
  "agent_votes": {
    "bullish": 3,
    "bearish": 0,
    "neutral": 1,
    "consensus": "STRONG_BULLISH"
  },
  "research_recommendation": "HOLD",
  "report": "\n======================================================================\nRISK MANAGER FINAL DECISION: LLY\n======================================================================\n**Analysis Date:** 2024-12-19 (HISTORICAL)\n**Portfolio:** $100,000\n\n## VERDICT: REJECT\n**Position:** No position taken\n**Confidence:** LOW\n\n## REASONING\nDespite the bullish sentiment surrounding Eli Lilly (LLY) due to the FDA's resolution of the GLP-1 drug shortage, the overall recommendation from our research manager is to HOLD with low confidence. The inability to conduct a comprehensive analysis due to a synthesis failure raises significant concerns about the robustness of our investment thesis. Given these uncertainties and the mixed evaluator opinions, it is prudent to pass on this trade to mitigate risk.\n\n## KEY FACTORS\n\u2022 FDA decision on GLP-1 drug\n\u2022 Low confidence in analysis\n\u2022 Mixed evaluator opinions\n\n## EVALUATOR SUMMARY\n- Aggressive: STRONG BUY @ 15.0%\n- Neutral: BUY @ 12%\n- Conservative: MINIMAL BUY @ 2%\n\n## AGENT CONSENSUS\n- Bullish Votes: 3/4\n- Bearish Votes: 0/4\n- Neutral Votes: 1/4\n- Overall: Strong Bullish\n\n## POSITION SIZING\n- Range: 0.0% - 0.0%\n- Final: 0.00% ($0.00)\n\n## RISK CONTROLS\n- Stop Loss: -15%\n- Profit Targets: +12.5%, +18.8%, +25%\n\n## CONDITIONS\n\u2022 Inability to generate full analysis\n\u2022 Default to HOLD recommendation\n\n======================================================================\n"
}